Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lidocaine patch 5%.

A M Comer1, H M Lamb

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|March 24, 2000
PubMed
Summary
This summary is machine-generated.

The lidocaine patch 5% effectively reduces pain intensity and provides relief for postherpetic neuralgia (PHN) by blocking sodium channels. Clinical trials showed significant pain reduction with minimal, mild skin irritation as the most common side effect.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

131I tositumomab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Cladribine: a review of its use in multiple sclerosis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Mizolastine: a review of its use in allergic rhinitis and chronic idiopathic urticaria.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Denileukin diftitox.

American journal of clinical dermatology·2001
Same author

Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.

PharmacoEconomics·2001
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Neurology
  • Dermatology

Background:

  • Postherpetic neuralgia (PHN) is a chronic pain condition often associated with neuropathic pain.
  • Topical lidocaine offers a potential treatment modality for localized pain relief.

Purpose of the Study:

  • To evaluate the efficacy and safety of lidocaine patch 5% for treating pain associated with PHN.

Main Methods:

  • Clinical trials were conducted over 12 hours to 24 days.
  • Patients with allodynia associated with PHN were treated with lidocaine patch 5% or a vehicle patch.
  • Pain intensity and relief were measured as primary outcomes.

Main Results:

  • Lidocaine patch 5% demonstrated a significant reduction in pain intensity compared to the vehicle patch.

Related Experiment Videos

  • Patients reported increased pain relief with the lidocaine patch.
  • The most frequent adverse events were mild skin redness or irritation at the application site, occurring similarly in both groups.

    • Conclusions:

    • Lidocaine patch 5% is an effective and well-tolerated treatment for pain associated with PHN.
    • The mechanism of action involves blocking neuronal sodium channels, leading to analgesic effects.
    • Few adverse events were reported, suggesting a favorable safety profile for topical lidocaine in PHN management.